Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reagan-Udall, Still Waiting For FDA Funding, Studies Drug Toxicity Pathways

Executive Summary

Created by Congress to help FDA modernize medical product development and evaluation, the foundation will receive its first influx of federal money to support overhead in fiscal 2012.

You may also be interested in...



Post-Market Drug Surveillance Research Methods Are Focus Of Reagan-Udall Program

The Reagan-Udall Foundation has established an organizing committee to help inform the design and structure of what its Innovation in Medical Evidence Development and Surveillance program’s post-market research methods should look like and develop the IMEDS charter.

Increased FDA China Inspections Backed By House Panel, While Purse Strings Pulled Still Tighter

Funds for the Reagan-Udall Foundation must come from the FDA commissioner’s office account, under successful amendment from Rep. DeLauro.

TB Regimen Could Pave Way For More FDA Involvement In Neglected Tropical Diseases

TB Alliance plans to seek FDA approval for its treatment regimen, which is beginning a Phase IIb trial, as the agency looks to respond to calls for a clearer and quicker pathway for NTD drugs.

Related Content

Topics

UsernamePublicRestriction

Register

PS054346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel